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Abstract
Background: Octanoate is a medium-chain fatty acid (MCFA) that is rich in milk and tropical
dietary lipids. It also accounts for 70% of the fatty acids in commercial medium chain triglycerides
(MCT). Use of MCT for weight control tracks back to early 1950s and is highlighted by recent
clinical trials. The molecular mechanisms of the weight reduction effect remain not completely
understood. The findings of significant amounts of MCFA in adipose tissue in MCT-fed animals and
humans suggest a direct influence of MCFA on fat cell functions.
Methods: 3T3-L1 adipocytes were treated with octanoate in a high glucose culture medium
supplemented with 10% fetal bovine serum and 170 nM insulin. The effects on lipogenesis, fatty acid
oxidation, cellular concentration of reactive oxygen species (ROS), and the expression and activity
of peroxisome proliferator receptor gamma (PPARγ) and its associated lipogenic genes were
assessed. In selected experiments, long-chain fatty acid oleate, PPARγ agonist troglitazone, and
antioxidant N-acetylcysteine were used in parallel. Effects of insulin, L-carnitine, and etomoxir on
β-oxidation were also measured.
Results: β-oxidation of octanoate was primarily independent of CPT-I. Treatment with octanoate
was linked to an increase in ROS in adipocytes, a decrease in triglyceride synthesis, and reduction
of lipogenic gene expression. Co-treatment with troglitazone, N-acetylcysteine, or over-
expression of glutathione peroxidase largely reversed the effects of octanoate.
Conclusion:  These findings suggest that octanoate-mediated inactivation of PPARγ might
contribute to the down regulation of lipogenic genes in adipocytes, and ROS appears to be involved
as a mediator in this process.
Background
Medium-chain fatty acids (MCFA) belong to a unique
type of fatty acids that is metabolized differently from
either long-chain fatty acids or carbohydrates. Dietary
medium-chain triglycerides (MCT) inhibit body fat mass
growth in both animals and human [1-10] Early studies
suggest that this effect might be caused by rapid absorp-
tion of MCT-derived MCFA and their β-oxidation in the
liver, which reduces the circulating fatty acids available to
the adipocytes [11]. This model is supported by the evi-
dence that MCFA enters the β-oxidation pathway in liver
mitochondria independent of carnitine palmitoyl trans-
ferase I (CPT-I) [12]. However, it does not explain the
findings that dietary MCT inhibits lipogenesis in adi-
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pocytes [13,14]. Furthermore, MCFA are recovered in the
adipose tissue fatty acids up to 30 mole % in both animals
and humans adapted to MCT diets [6,15-17]. These find-
ings imply that a substantial influx of MCFA into the adi-
pocytes occurs in vivo, which might affect adipose tissue
function more than previously appreciated. Indeed, we
found that a reduction in fat mass was associated with
reduced expression of lipogenic genes and adipocyte tran-
scription factors in MCT-fed animals [6]. This effect was
reproduced in cultured adipocytes treated with octanoate
[18]. When added to differentiating rodent preadipocytes,
MCFA also inhibits fat accumulation and reduces expres-
sion of adipocyte specific proteins [19,20]. In this study,
we provide new evidence that octanoate suppresses lipo-
genesis, at least in part, by inactivating the key adipocyte
transcription factor, peroxisome proliferator-activated
receptorγ (PPARγ). Furthermore, our data revealed, for the
first time, an involvement of reactive oxygen species
(ROS) as a possible intermediate component that might
regulate the anti-lipogenic effects.
Materials and methods
Materials
3T3-L1 cell line was purchased from American Type Cul-
ture Collection (Manassas, VA). The HEK293A cell line
was from Invitrogen (Long Island, NY). Cell culture sup-
plies were from Fisher Scientific (Agawa, MA) or Gibco
Life Technology (Long Island, NY). TransLucent reporter
vector for PPARγ [PPRE(+)-Luc reporter gene containing
the PPARγ responsive element (PPRE)] [21] was from
Panomics, Inc (Redwood City, CA). Renilla luciferase con-
trol reporter vector pRL-null and a dual luciferase reporter
assay kit system were from Promega (Madison, WI).
Recombinant adenovirus encoding glutathione peroxi-
dase and its parental adenovirus Ad-5 were from Genecore
of Iowa University (Ames, IA). Troglitazone was from Bio-
mol Inc (Plymouth meeting, PA). Other chemicals, rea-
gents, and solvents were from Sigma (St. Louis, MO),
unless noted elsewhere.
Cell culture
3T3-L1 preadipocytes were grown in Dulbecco's mini-
mum essential medium (DMEM) with 10% calf serum,
pencicillin (100 IU), and streptomycin (100 IU). Differ-
entiation was induced on day 2 post confluence using
DMEM with 10% fetal bovine serum (FBS), 0.5 mM meth-
ylisobutylxanthine, 1 μM dexamethasome, and 170 nM
insulin. After 48 h, medium was changed to DMEM plus
10% FBS and 170 nM insulin. Cells were used for incuba-
tion with octanoate or other effectors 6–9 days thereafter,
at which point >90% of the cells accumulated lipid drop-
lets.
Lipogenesis
Triglycerides (TAG) synthesis in adipocytes uses both pre-
made and de novo synthesized fatty acids, with the glycerol
backbone comes primarily from glucose-derived glycerol-
3-phosphate. In this work, we assess the effects of
octanoate on each of these steps using [9,10-3H] triolein
(1 μCi/ml, 0.5% lipid emulation, measures lipoprotein
lipase activity), 3H2O (25 μCi/ml, measures fatty acid syn-
thase activity), and [U-3H] glucose (10 μCi/ml, measures
net TAG synthesis) as the substrates. Cells were incubated
with labeled substrates individually for 3 h (a linear range
of 0 – 5 h was confirmed in preliminary experiments),
washed 4 times with warm PBS containing 1% BSA. Cells
were then lysed, extracted with organic solvent, and the
lipid components were separated by TLC [22]. The TAG
fraction was scraped for scintillation counting directly or
for methylation reaction as described before [22]. After
removal of the methyl acyl esters, the aqueous phase con-
taining the glycerol moiety was used for scintillation
counting [22]. Non-specific binding was measured by
exposing cells to the same medium but washed immedi-
ately (usually <5% of that incorporated into the cellular
TAG pool after the 3 h incubation).
β-oxidation
To measure β-oxidation of octanoate, cells were grown in
T25 flask, incubated in serum-free DMEM containing
0.5% BSA overnight, and then treated with exogenous [1-
14C] octanoate (0.5 mM, 1 μCi/ml) together with the
desired effectors for 2 h. The release of 14CO2was meas-
ured as described before [22]. To measure the β-oxidation
of oleate, cells grown in 6-well plates were pre-incubated
in serum-free DMEM with [9,10-3H] oleate (1 μCi/ml,
<0.1 μM) overnight. Exogenous oleate was removed by
washing the cells with PBS containing 0.5% BSA. Cells
were then incubated with or without insulin or L-carnitine
for 2 h. The release of 3H2O into the medium was meas-
ured as described [23].
PPARγ transcriptional activity
HEK293A cells were transfected with PPARγ2 using a
recombinant retrovirus encoding a full-length cDNA of
mouse PPARγ2 (a gift from Dr. Spiegelman BM, Harvard
University) followed by neomycin selection. The 293A-
PPARγ2 cells thus generated were then grown in DMEM
with 10% FBS to 60% confluence and co-transfected with
PPRE(+)-Luc reporter and Rluc reporter vectors using
Effectene Transfection Reagent from Qiagen (Valencia,
CA). Octanoate or other effectors were added to cell cul-
ture 48 h after the transfection. Cells were harvested for a
dual luciferase assay using a commercial kit (Promega).
RNA isolation and real-time RT-PCR analysis
Total RNA was isolated using Trizol method (Invitrogen,
Carlsbad, CA) and reverse transcription from mRNA toNutrition & Metabolism 2006, 3:30 http://www.nutritionandmetabolism.com/content/3/1/30
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cDNA was performed as described before [24]. Intron-
spanning PCR primers were designed using a web-based
program provided by Roche. House keeping gene mouse
HPRT was used as the endogenous reference. SYBG-based
real-time PCR was conducted in 20 μl reaction mix con-
taining 10 μl PCR enzyme mix (Qiagen), 2 μl cDNA, 3 μl
primer mix (final 1.5 μM for each primer), and 5 μl nucle-
ase-free water, using a Rotorgene 3000A system. Amplifi-
cation parameters consisted of initial enzyme activation at
95°C for 10 min and 45 cycles of three-step PCR (dena-
ture 5 s at 95°C, annealing 10 s at 60°C, and extension 20
s at 72°C). The specificity of products generated for each
set of primers was examined for each fragment using a
melting curve and gel electrophoresis. Reactions were run
in triplicates and data calculated as the change in cycle
threshold (Ct) for the target gene relative to the Ct for
HPRT. To confirm the relationship between Ct values and
mRNA levels, primers were calibrated by using serial dilu-
tions of cDNA.
Cellular ROS
Cellular ROS was measured with a protocol modified
from the literature [25]. Briefly, 3T3-L1 adipocytes were
incubated with octanoate with or without the antioxidant,
N-acetylcysteine (NAC), for 24 h. Dichlorofluorescein
diacetate (2 μM, DCFH-DA, Molecular Probe, Eugene,
OR), a cell permeable nonfluorescent precursor, was then
added to the cells and the incubation was extended for
another 30 min. Within the cells, DCFH-DA is hydrolyzed
by nonspecific esterases to release DCF, which is readily
oxidized by intracellular ROS. The oxidized product emits
green fluorescence (ex 488 nm, em 525 nm). At the end of
incubation, cells were washed with warm KRB buffer and
immediately imaged under a polarizing/fluorescent
microscope (Nikon Eclipse TE200). Caution was taken to
ensure that cells from different samples were exposed to
excitation for identical period of time (30 s) and photo-
graphed using the same exposure time (15 s) and receiver
gain (1.0) using a Nikon digital camera (original magnifi-
cation 10x).
Statistical methods statistics
Statistics
Data are shown as means +/- SE. Comparison between
two groups of data was made using Student's t test. For
others, results were analyzed using one-way ANOVA and
Duncan's multiple comparison tests. Differences were
considered statistically significant when p < 0.05.
Results
Octanoate inhibits TAG synthesis and reduces expression 
of selected lipogenic genes
In this study, TAG synthesis was measured by isotope-trac-
ing method using substrates at different stages of the bio-
synthesis cascade. As shown in Figure 1, pre-incubation
with octanoate for 3 days substantially inhibited the de
novo fatty acid synthesis (Fig. 1A), the incorporation of
exogenous fatty acids into TAG (Fig. 1B), and the net syn-
thesis of intracellular TAG (Fig. 1C). These results indi-
cated that octanoate induced a comprehensive inhibition
of lipogenesis. Since measurement was done in the
absence of octanoate, the inhibitory effect was likely sus-
tained through modulation of gene expression. To test
this possibility, we performed quantitative real-time PCR
analysis for selected lipogenic genes. As shown in Figure 2,
octanoate induced a large decrease in the expression of
key enzymes involved in fatty acid uptake and triglyceride
synthesis. These included lipoprotein lipase (LPL), fatty
acid synthase (FAS), and diacylglycerol acyltransferase 2
(DGAT2). The reduction in LPL and FAS correlates with
the specific reduction in fatty acid uptake from exogenous
triolein (Fig. 1B) and de novo fatty acid synthesis from
H2O (Fig. 1A), respectively. A reduction in DGAT2 might
contribute to reduction of overall triglyceride synthesis
(Fig. 1A–C). Besides, octanoate also inhibited the expres-
sion of CD36, a protein that has been shown to be
required for efficient lipid storage [26]. Among the targets
tested, CD36 and LPL have been demonstrated as PPARγ
target genes [27,28]. As for FAS and DGAT2, although
with no defined PPRE in their promoters, both are drasti-
cally induced during preadipocyte differentiation, a proc-
ess that is tightly controlled by the activation of PPARγ.
Hence, these two genes can be considered as indirect
The effects of octanoate on lipogenesis in adipocytes Figure 1
The effects of octanoate on lipogenesis in adipocytes. 
Six days after induction of differentiation, 3T3-L1 adipocytes 
were incubated with octanoate (1 mM, oct) mixed with 
DMEM containing 10% FBS and 170 nM insulin for 3 days. 
Exogenous octanoate were then removed and cells were 
incubated for 3 h in the same medium with 3H2O (A), [9,10-
3H] triolein (B), and [U-3H] glucose (C). The incorporation 
of the corresponding isotope into the cellular TAG-fatty 
acids (TAG-FA, A&B) and TAG-glycerol (C) were measured. 
Data are mean +/- SE, n = 3. *p < 0.05 compared to control.
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downstream targets of PPARγ. It is not surprising that we
detected a large decrease in mRNA of PPARγ in association
with the changes in the aforementioned lipogenic genes
(Fig. 2). In parallel, we also detected a similar decrease in
the expression of PPARδ (Fig. 2). Co-incubation with a
synthetic PPARγ agonist, troglitazone, largely restored the
expression of the lipogenic genes as well as PPARγ amd
PPARδ (Fig. 2). Troglitazone also caused a 1.5 fold
increase in TAG synthesis and diminished the inhibitory
effect of octanoate ([19] and data not shown).
β-oxidation of octanoate is largely independent of CPT-I
Results above suggest that sustained anti-liogenic effect of
octanoate is correlated with reduced expression of lipo-
genic genes, and the effect was reversible by co-treatment
with a PPARγ synthetic ligand. This distinguishes
octanoate from common fatty acids that have been shown
to activate PPARγ [29-36]. One of the unique properties of
octanoate is that it might be activated within the mito-
chondria [12] and enters the β-oxidation pathway inde-
pendent of CPT-I [37]. This allows octanoate to be β-
oxidized in the presence of glucose and insulin, condi-
tions under which long-chain fatty acids are primarily
channeled to esterification. This prediction, however, has
not been firmly established in adipocytes. Peculiarly, sev-
eral isoforms of medium chain acyl CoA synthetase have
been recently identified and cloned [38-40], with none
expressed to an appreciable level in adipocytes [41].
Because β-oxidation is linked to ROS generation [25,42-
44], the potential molecular signals for regulation of lipo-
genesis, it is important to test whether β-oxidation of
octanoate is truly independent of CPT-I in adipocytes. For
this purpose, we measured the generation of 14CO2 from
octanoate and tested its response to insulin, L-carnitine,
oleate, and etomoxir, factors that modulate CPT-I via dif-
ferent mechanisms. As shown in Figure 3A, β-oxidation of
octanoate was slightly inhibited (~18%) by insulin, a hor-
mone that promotes the generation of the natural inhibi-
tor of CPT-I [37], and Etomoxir, a pharmaceutical
inhibitor of CPT-I. On the other hand, L-carnitine, an acti-
vator of CPT-I, caused a ~60% inhibition of octanoate oxi-
dation. A combination of L-carnitine and exogenous
oleate further enhanced the inhibition (> 85%). In con-
trast, β-oxidation of oleate was increased by L-carnitine
more than 2 fold but inhibited by insulin by about 60%
(Fig. 3B), consistent with the literature [37]. These results
indicate that in adipocytes, octanoate was mainly oxi-
dized independent of CPT-I (> 80%). A small fraction (<
20%), that was sensitive to insulin and etomoxir, might
be activated in the cytosol and hence depend on CPT-I to
enter the mitochondria. The observation that L-carnitine
inhibited, rather than promoted, β-oxidation of octanoate
suggests that activation of CPT-I largely increased the
transport of endogenous fatty acids into the β-oxidation
pathway which compete with octanoate for the enzymes
downstream from CPT-1. This competition was further
enhanced in the presence of added oleate.
The regulation of β-oxidation of octanoate (A) and oleate (B)  in adipocytes Figure 3
The regulation of β-oxidation of octanoate (A) and 
oleate (B) in adipocytes. Cells were serum-starved over-
night in DMEM containing 0.5% BSA. (A) Cells were then 
incubated in DMEM for 2 h with exogenous octanoate [0.5 
mM, 1 μCi/ml)] alone or together with insulin (170 nM, ins), 
etomoxir (30 μM, etx), L-carnitine (5 mM, L-car), or L-carni-
tine plus oleate (0.5 mM, L-car + ole). The release of 14CO2 
was measured. (B) Cells were pre-incubated with [9,10-3H] 
oleate overnight. After washing off the exogenous oleate, 
cells were incubated with L-carnitine (5 mM) or insulin (170 
nM) in DMEM for 2 h. The release of 3H2O into the medium 
was measured. Results are mean +/- SE. Values indicated with 
different letters are significantly different (p < 0.05).
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The effects of octanoate on expression of selected lipogenic  genes and the antagonizing effects of troglitazone Figure 2
The effects of octanoate on expression of selected 
lipogenic genes and the antagonizing effects of trogli-
tazone. Cells were incubated with octanoate (1 mM) for 24 
h with or without troglitazone (5 μM), using DMSO as the 
vehicle. (Upper panel) The expression of CD36, diacylglyc-
erol acyltransferase 2 (DGAT2), fatty acid synthase (FAS), 
and lipoprotein lipase (LPL) were analyzed by RT-qPCR using 
house keeping gene HPRT as the endogenous reference. The 
results were normalized to control cells. Results are mean +/
- SE, n = 3, *p < 0.05.
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Octanoate-induced ROS generation and inhibition of 
PPARγ activity: effects of N-acetylcysteine
A common consequence of fatty acid oxidation, as com-
pared to that of glucose, is the generation of NADH and
FADH2. This increases electron flow through the mito-
chondrial electron transport chain and increases electron
leak to produce ROS [45,46]. Because ROS has been
shown to activate the stress-responsive protein kinases
that lead to the inhibition of PPARγ [47-49], we hypothe-
size that ROS might be an important mediator for the
anti-lipogenic effects of octanoate. To test this possibility,
we first measured the ROS intensity in adipocytes treated
with octanoate. As shown in Figure 4A, incubation with
octanoate for 24 h significantly increased the intracellular
ROS intensity, which was blocked by co-treatment with
N-acetylcysteine. Secondly, we measured the effects of
octanoate on PPARγ transcriptional activity using a
PPRE(+)-Luc reporter gene assay. As shown in Figure 4B,
pre-incubation with octanoate for 24 h inhibited PPARγ
transcription activity by about 50%, and this inhibition
was blocked by a co-treatment with N-acetylcysteine. As a
positive control, we show that exogenous ROS, generated
by a mixture of xanthine and xanthine oxidase, also inhib-
ited PPARγ transcriptional activity, an effect blocked by N-
acetylcysteine. Finally, we transfected mature adipocytes
with the adenovirus encoding glutathione peroxidase 1
(GPx-1), a cytosolic isoform of GPx which detoxifies ROS
[47]. As shown in Figure 4C, octanoate inhibited TAG syn-
thesis by about 40% in adipocytes transfected with the
parent adenovirus Ad-5. This inhibition was offset by
over-expression of GPx-1.
The effects of octanoate on the generation of reactive oxygen species (ROS, A), PPARγ transcription activity (B) and TAG syn- thesis (C), and the effects of antioxidants Figure 4
The effects of octanoate on the generation of reactive oxygen species (ROS, A), PPARγ transcription activity 
(B) and TAG synthesis (C), and the effects of antioxidants. For (A), 3T3-L1 adipocytes were incubated with octanoate 
(1 mM) for 24 h with or without N-acetylcysteine (NAC, 20 mM) followed with the measurement of ROS by the DCF assay. 
Results are representative of at least three independent experiments. For (B), 293A-PPARγ2 cells were co-transfected with the 
plasmid DNA vector encoding a PPRE(+)-Luc reporter gene or the Rluc control reporter gene. After 24 h, cells incubated with 
octanoate (1 mM) or a mixture of xanthine/xanthine oxidase (200 μM/30 μU/ml). Cells were harvested after 24 h and analyzed 
using a dual luciferase assay. For (C), 3T3-L1 adipocytes were infected with recombinant adenovirus encoding GPx1 or its 
parental virus Ad-5. After 24 h, Cells were incubated with octanoate (1 mM) for another 3 days. TAG synthesis from [U-3H] 
glucose was measured as described in Figure 1. For (B&C), Results are mean +/- SE, n = 3, *p < 0.05 compared to control.
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Discussion
Fatty acid oxidation is normally activated only under fast-
ing conditions when circulating levels of insulin and glu-
cose are low. Conversely, lipogenesis is down-regulated
by fasting. The mechanistic link between these two events,
however, has not been established. In this work, we pro-
vided the first evidence that medium-chain octanoate can
be β-oxidized in adipocytes independent of CPT-I regula-
tion. Hence, supplement of octanoate maintains active β-
oxidation in the presence of insulin and glucose. This is
correlated with inhibition of lipogenesis and reduction of
lipogenic gene expression. In other words, octanoate
induces a metabolic state in adipocytes mimicking a fast-
ing condition without actual hormone/nutrient depriva-
tion. Our results also demonstrated that ROS might be
involved as a mediator for octanoate in lowering PPARγ
activity, the master control of lipogenic gene expression.
As extensively reviewed previously, PPARγ is a prototypi-
cal member of the nuclear receptor superfamily which
integrates the control of energy, lipid and glucose, homer-
ostasis [50-54]. PPARγ binds a variety of small lipophilic
compounds derived from metabolism and nutrition.
These ligands, in turn, determine cofactor recruitment and
regulate the transcription of a variety of metabolic genes.
Recent literature highlights the development of partial
agonists of PPARγ to block adipogenesis and reduce fat
mass development [54-59]. In one of our previous stud-
ies, we proposed that octanoate might act as a partial ago-
nist for PPARγ because it can potentially bind to PPARγ as
does the long-chain fatty acids [29,60], hence competi-
tively blocking the binding of the latter or other endog-
enous ligands. This model was supported, but not proved,
by the findings that the anti-adipogenic [19] and anti-
lipogenic (this work) effects of octanoate was efficiently
blocked by selected synthetic PPARγ agonists.
The current findings that octanoate induced ROS genera-
tion in adipocytes suggest that octanoate might also mod-
ulate PPARγ activity indirectly via the ROS signaling
pathways. It has been well established that ROS activates
the stress-responsive protein kinases [61,62], which either
directly or indirectly inhibit PPARγ activity [47-49,62-67].
In our preliminary studies, we found that octanoate also
induced sustained activation of Erk1/2 and JNK/SAPK
(data not shown). How these kinase pathways are
involved in the regulation of PPARγ activity and lipogen-
esis in our cell system and, more importantly, in primary
adipocytes, are currently under investigation.
Inhibition of adipocyte lipogenesis can be a useful tool for
the prevention of obesity. In this regard, our studies con-
tribute to the scientific basis for the application of MCT in
dietary weight management. On the other hand, a com-
plete inhibition of fat mass growth is disastrous since adi-
pocytes play important roles in physiological functions of
mammals. Compared to the pharmaceutical inhibitors of
lipogenesis [68,69], the effects of octanoate can be consid-
ered as moderate and yet might be more desirable for
physiological regulation of body fat mass without
adversely affecting normal fat tissue functions. According
to recent surveys, a majority of the middle age population
is moderately over-weighed (BMI 23–27), and a slight
increase in BMI in this range is associated with a greater
risk for metabolic syndrome [70,71]. It will be of impor-
tant social and economical values if MCT can be used for
body weight regulation in this sub-population, as demon-
strated by a recent clinical trial [5].
Conclusion
This study demonstrated that octanoate had a direct
inhibitory effect on fat storage in adipocytes under condi-
tions that normally favor lipogenesis. This was related to
its unique β-oxidation mechanism which links to elevated
cellular ROS levels and subsequent inactivation of PPARγ.
The exact mechanism by which PPARγ is inactivated, in
particular, how ROS is involved in this process, still
remains to be elucidated. Furthermore, ROS is known to
have diverse and complex molecular targets, which might
directly or indirectly influence the activities of additional
adipocyte transcription factors or modify selected lipo-
genic proteins [44,71]. Elucidation of these mechanisms
will be helpful for the application of MCT for dietary
intervention to prevent obesity and may reveal possible
pharmaceutical targets to modulate fat metabolism.
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